| EV Resources Limited (EVR) ORDINARY FULLY PAID |
Materials |
$27 |
Maiden Drilling Set to Commence at Los Lirios Project
|
15 Dec 2025 9:11AM |
$0.009 |
$0.009 |
fallen by
0%
|
|
EVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden drill program to commence in early January 2026.
- Fully funded program targeting high-grade antimony under historical workings.
- Phase 1 comprises 1,500-2,000 meters of diamond drilling.
- Aim to deliver maiden JORC resource by Q3 2026.
- Parallel advancement at Los Lirios and Tecomatlán Plant for production readiness.
- Part of a larger 2026 exploration campaign to unlock full scale potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$61 |
PTX secures EU Authorisation to commence PTX-100 Trial
|
15 Dec 2025 9:10AM |
$0.089 |
$0.058 |
fallen by
34.83%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient Therapeutics Limited secures EU authorisation to commence the PTX-100 trial.
- The trial targets patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL) in Italy.
- PTX-100 is a first-in-class therapy targeting cancer growth pathways.
- The trial is advancing into Phase 2a with recruitment beginning in Europe.
- The European Clinical Trials Information System (CTIS) granted the authorisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$102 |
Update - Notification of buy-back - CAM
|
15 Dec 2025 9:10AM |
$0.690 |
$0.710 |
risen by
2.90%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$84 |
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
|
15 Dec 2025 9:09AM |
$0.265 |
$0.355 |
risen by
33.96%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Patient enrolment completed for Phase 2 aGvHD clinical trial.
- 65 participants enrolled across the USA, Europe, and Australia.
- Participants received either steroids plus CYP-001 or steroids plus placebo.
- Primary evaluation period to conclude in March 2026, results expected by June 2026.
- CYP-001 is designed to improve response rates and survival in aGvHD.
- Phase 1 trial showed 87% overall response and no serious adverse events.
- CYP-001 has Orphan Drug Designation by the US FDA for aGvHD treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,526 |
LNW Form 3-Amendment (Fine Capital)
|
15 Dec 2025 9:09AM |
$151.410 |
$131.105 |
fallen by
13.41%
|
|
| Intelligent Monitoring Group Limited (IMB) ORDINARY FULLY PAID |
Industrials |
$217 |
Trading Halt
|
15 Dec 2025 9:08AM |
$0.640 |
$0.528 |
fallen by
17.58%
|
|
IMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Intelligent Monitoring Group Limited.
- Pending announcement regarding proposed equity raising.
- Halt effective from 15 December 2025.
- Trading expected to resume on 17 December 2025 or upon announcement.
- No known reasons to deny the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$404 |
Suspension from Quotation
|
15 Dec 2025 9:08AM |
$1.030 |
$0.885 |
fallen by
14.08%
|
|
NVA - Price-sensitive ASX Announcement
Full Release
Key Points
- Nova Minerals Limited requests voluntary suspension of its securities.
- The suspension is under ASX Listing Rule 17.2.
- Suspension is due to pending announcement on proposed capital raising.
- Trading halt was requested prior on 11 December 2025.
- Expected end of suspension on 17 December 2025.
- No known impediments to granting the suspension.
- Request authorized by the Executive Directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Meridian Energy Limited (MEZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$12,376 |
Financial assistance in connection with FY26 Equity Plan
|
15 Dec 2025 9:08AM |
$4.800 |
$4.690 |
fallen by
2.29%
|
|
| Brazilian Rare Earths Limited (BRE) ORDINARY FULLY PAID |
Materials |
$1,426 |
Amargosa Bauxite Presentation
|
15 Dec 2025 9:08AM |
$4.000 |
$5.170 |
risen by
29.25%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,526 |
LNW Form 4-Amendment (Fine Capital)
|
15 Dec 2025 9:07AM |
$151.410 |
$131.105 |
fallen by
13.41%
|
|
| BKI Investment Company Limited (BKI) ORDINARY FULLY PAID |
Financials |
$1,412 |
BKI 12 December 2025 Weekly NTA
|
15 Dec 2025 9:06AM |
$1.705 |
$1.750 |
risen by
2.64%
|
|
| Epiminder Limited (EPI) ORDINARY FULLY PAID |
Health Care |
$145 |
Change of Director's Interest Notice DO
|
15 Dec 2025 9:06AM |
$1.150 |
$0.830 |
fallen by
27.83%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$243 |
Remplir Regulatory Application for US$750m EU-UK Market
|
15 Dec 2025 9:05AM |
$1.020 |
$0.895 |
fallen by
12.25%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell submits regulatory application to BSI for EU and UK markets.
- The EU and UK nerve repair market represents a US$750 million opportunity.
- Application supported by 81.1% treatment success rate in real-world evidence study.
- Expected 'CE' and 'UKCA' certification by 3Q CY26.
- Orthocell has a strong balance sheet with approximately $50 million in cash.
- Orthocell plans to utilize in-country distributors and key opinion leaders for market strategy.
- Remplir already approved in various countries including the US, Australia, and Hong Kong.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,561 |
FDA approves DAYBUE STIX (trofinetide), powder formulation
|
15 Dec 2025 9:05AM |
$19.010 |
$12.325 |
fallen by
35.17%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approved DAYBUE STIX, a new powder formulation of trofinetide.
- DAYBUE STIX is designed for Rett syndrome patients aged two years and older.
- The new formulation offers flexible dosing options by mixing with liquids.
- Neuren Pharmaceuticals will receive royalties from the sales.
- Approval was based on bioequivalence with the original DAYBUE oral solution.
- DAYBUE STIX expected to be available in early 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$240 |
CFO transition
|
15 Dec 2025 9:04AM |
$0.200 |
$0.230 |
risen by
15%
|
|
| Great Southern Mining Limited (GSN) ORDINARY FULLY PAID |
Materials |
$37 |
EMERGING DISCOVERY AT AMY CLARKE
|
15 Dec 2025 9:04AM |
$0.029 |
$0.037 |
risen by
27.59%
|
|
GSN - Price-sensitive ASX Announcement
Full Release
Key Points
- Great Southern Mining Limited (GSN) is actively involved in exploration activities through its subsidiary East Laverton Exploration Pty Ltd.
- The Amy Clarke prospect is part of the Duketon Greenstone Belt, featuring significant geological structures conducive to gold mineralization.
- Recent drilling at the Amy Clarke prospect includes several drill holes with notable gold intersections.
- The exploration methods involve air-core drilling and sampling, with intervals showing gold assay results above 0.2 g/t Au.
- Future exploration efforts will focus on assessing recent drill results to further understand the mineralization at Amy Clarke.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fortifai Ltd (FTI) ORDINARY FULLY PAID |
Communication Services |
$138 |
Nol8 Investor Presentation
|
15 Dec 2025 9:03AM |
$0.200 |
$0.430 |
risen by
115%
|
|
FTI - Price-sensitive ASX Announcement
Full Release
Key Points
- Nol8 technology enables 'Data-in-Motion' for real-time data processing.
- Achieves millisecond-grade latency and supports data volumes of 100 Gbps.
- Operates at a scale equivalent to 5,000 CPUs with significant cost savings.
- Built on advanced algorithms, machine learning, and hardware acceleration.
- Backed by world-class academic research and developed by industry experts.
- Nol8 is suited for gaming, finance, AI, and other critical workload applications.
- Aims to enhance gaming infrastructure with real-time decision-making capabilities.
- Nol8 technology reduces storage requirements and computing power needs.
- Developed by alumni of Israel’s elite intelligence unit, Unit 8200.
- Provides scalable solutions for both cloud and on-premises environments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ariadne Australia Limited (ARA) ORDINARY FULLY PAID |
Industrials |
$101 |
Update - Notification of buy-back - ARA
|
15 Dec 2025 9:03AM |
$0.500 |
$0.520 |
risen by
4%
|
|
| Corella Resources Ltd (CR9) ORDINARY FULLY PAID |
Materials |
$18 |
Trading Halt
|
15 Dec 2025 9:02AM |
$0.004 |
$0.013 |
risen by
225%
|
|
CR9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Corella Resources Ltd
- Halt pending capital raising announcement
- Halt effective until 17 December 2025 or announcement
- Compliance with ASX Listing Rule 17.1
- No other information necessary for the market
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$124 |
Update - Notification of buy-back - ANG
|
15 Dec 2025 9:02AM |
$0.195 |
$0.200 |
risen by
2.56%
|
|
| Fortifai Ltd (FTI) ORDINARY FULLY PAID |
Communication Services |
$138 |
Nol8 Data-In-Motion Technology Licence
|
15 Dec 2025 9:02AM |
$0.200 |
$0.430 |
risen by
115%
|
|
FTI - Price-sensitive ASX Announcement
Full Release
Key Points
- Fortifai Limited acquires FastAI Pty Ltd to secure Nol8 technology license.
- Nol8 is a 'Data-in-Motion' engine designed for real-time data processing.
- Nol8 technology enhances data economics by storing only relevant data.
- Nol8 offers up to 400× latency improvement and 160× performance uplift.
- Single Nol8 appliance equals the performance of 5,000 CPUs.
- Supports 100 Gbps throughput with deterministic performance.
- Applications include AI, finance, gaming, data storage, and cybersecurity.
- Technology supports both cloud and on-premises solutions.
- Developed through five years of research with multiple proofs-of-concept.
- Founding team includes experts from Technion, NVIDIA, and 8200 Unit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pacific Resources Limited (PXR) ORDINARY FULLY PAID |
Energy |
$5 |
Cleansing notice
|
15 Dec 2025 9:01AM |
$0.002 |
$0.002 |
fallen by
25%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$734 |
Weekly Estimate NTA for 12.12.2025
|
15 Dec 2025 9:01AM |
$3.390 |
$3.490 |
risen by
2.95%
|
|
| Osmond Resources Limited (OSM) ORDINARY FULLY PAID |
Materials |
$72 |
Third Drill Hole Confirms Heavy Mineral Scale Potential
|
15 Dec 2025 9:01AM |
$0.865 |
$0.520 |
fallen by
39.88%
|
|
OSM - Price-sensitive ASX Announcement
Full Release
Key Points
- Third drill hole SOR-02 confirms scale potential for critical heavy minerals.
- High-grade mineralization including titanium, zirconium, and rare earth elements found.
- Drill hole SOR-02 located 1.7km from previous successful holes.
- Zone 1 shows significant potential, covering approximately 10.67 km2.
- Osmond Resources plans further drilling and a scoping study in 1H CY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,964 |
Update - Notification of buy-back - WHC
|
15 Dec 2025 9:00AM |
$7.730 |
$8.430 |
risen by
9.06%
|
|